Ionis Pharmaceuticals, Biogen deal

Biogen exercised a 2012 option to license exclusive, worldwide rights to develop and commercialize nusinersen from Ionis after the product met a co-primary endpoint in the Phase III ENDEAR trial to treat infantile-onset spinal muscular atrophy (SMA). Biogen will be responsible for all development, regulatory and commercialization activities and costs. Ionis will complete the product’s Phase III trials and work with Biogen on regulatory submissions. The companies expect to submit regulatory applications for the antisense oligonucleotide that modulates splicing of survival of motor neuron 2 centromeric (SMN2) mRNA by year end. ...